ADAM, a non-hormonal male contraceptive, shows promise with a favorable safety profile and sustained efficacy in early trials. FDA updates testosterone product labels, removing cardiovascular risk ...
FDA approvals in 2025 included Anktiva, mitomycin, and gemcitabine intravesical systems for BCG-unresponsive and low-grade intermediate-risk NMIBC. Real-world data supported the efficacy and safety of ...
"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...
Nogapendekin alfa inbakicept combined with BCG shows promise for BCG-unresponsive NMIBC CIS, with a 71% complete response rate in a single-arm trial. The European Medicines Agency's conditional ...
The Zenflow Spring Implant offers a reversible, durable BPH treatment, preserving natural anatomy with a spring-like implant. The BREEZE study showed a 60% responder rate and 37% IPSS improvement, ...
Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...
The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback